Clearside Biomedical Files 8-K on Officer/Director Changes
Ticker: CLSDQ · Form: 8-K · Filed: Apr 16, 2024 · CIK: 1539029
| Field | Detail |
|---|---|
| Company | Clearside Biomedical, Inc. (CLSDQ) |
| Form Type | 8-K |
| Filed Date | Apr 16, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001, $40,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, officer-changes, financial-reporting
TL;DR
Clearside Biomedical 8-K: Leadership changes and financial updates filed April 16, 2024.
AI Summary
Clearside Biomedical, Inc. filed an 8-K on April 16, 2024, reporting on the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements. The filing also includes a Regulation FD Disclosure and Financial Statements and Exhibits.
Why It Matters
This filing indicates potential shifts in the company's leadership and governance structure, which could impact strategic direction and operational oversight.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of corporate governance and financial information, not indicating immediate operational or financial distress.
Key Players & Entities
- Clearside Biomedical, Inc. (company) — Registrant
- April 15, 2024 (date) — Date of earliest event reported
- April 16, 2024 (date) — Date of report
FAQ
What specific officer or director positions were affected by the changes reported in this 8-K?
The filing indicates changes related to 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers,' but does not specify the exact positions in the provided text.
Are there any details about new compensatory arrangements for officers mentioned in the filing?
The filing lists 'Compensatory Arrangements of Certain Officers' as an item, but the specific details of these arrangements are not included in the provided text.
What is the significance of the 'Regulation FD Disclosure' item in this filing?
A Regulation FD Disclosure ensures that material non-public information is broadly disseminated to the public, preventing selective disclosure.
Does the filing provide any updated financial statements for Clearside Biomedical?
The filing includes 'Financial Statements and Exhibits' as an item, suggesting that financial information is being provided, though the specifics are not detailed in the excerpt.
What is the primary business of Clearside Biomedical, Inc. based on its SIC code?
Clearside Biomedical, Inc. is classified under 'PHARMACEUTICAL PREPARATIONS [2834]' according to its Standard Industrial Classification code.
Filing Stats: 1,014 words · 4 min read · ~3 pages · Grade level 9.5 · Accepted 2024-04-16 07:15:11
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share CLSD The Nasdaq Stock Mar
- $40,000 — r. Gibney will be entitled to receive a $40,000 annual retainer for his service as dire
Filing Documents
- clsd-20240415.htm (8-K) — 46KB
- clsd-ex99_1.htm (EX-99.1) — 18KB
- img171462827_0.jpg (GRAPHIC) — 98KB
- 0000950170-24-044594.txt ( ) — 316KB
- clsd-20240415.xsd (EX-101.SCH) — 24KB
- clsd-20240415_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On April 15, 2024, the Company issued a press release announcing the appointment of Mr. Gibney to the Board. A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K. The information set forth in this Item 7.01 and contained in the press release furnished as Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), and is not incorporated by reference into any of the Company's filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in any such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 99.1 Press Release, dated April 16, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: April 16, 2024 CLEARSIDE BIOMEDICAL, INC. By: /s/ Charles A. Deignan Name: Charles A. Deignan Title: Chief Financial Officer